Loading...
•
Sep 30, 2022
Evolent Health Q3 2022 Earnings Report
Evolent Health's Q3 2022 results were announced, featuring revenue growth, net income, and adjusted EBITDA.
Key Takeaways
Evolent Health reported strong Q3 2022 results with a 58.5% increase in revenue to $352.6 million, a net income of $2.1 million, and an adjusted EBITDA of $28.1 million. The company also announced three new operating partnerships and achieved significant sales momentum.
Revenue increased by 58.5% to $352.6 million compared to Q3 2021.
Net income attributable to common shareholders was $2.1 million, resulting in a net income margin of 0.6%.
Adjusted EBITDA reached $28.1 million, with an adjusted EBITDA margin of 8.0%.
Total Lives on Platform reached 19.5 million, including 2.1 million Evolent Health Services Lives and 17.4 million Clinical Solutions Lives.
Forward Guidance
For Q4 2022, Evolent Health expects revenue between $361 million and $381 million and adjusted EBITDA between $24 million and $29 million. For full year 2022, revenue is expected to be between $1.33 billion and $1.35 billion, and adjusted EBITDA is expected to be between $98 million and $103 million.
Positive Outlook
- Revenue for Q4 2022 is expected to be in the range of approximately $361.0 million to $381.0 million.
- Adjusted EBITDA for Q4 2022 is expected to be in the range of approximately $24.0 million to $29.0 million.
- Revenue for the year ending December 31, 2022 is expected to be in the range of approximately $1.33 billion to $1.35 billion.
- Adjusted EBITDA for the year ending December 31, 2022 is expected to be in the range of approximately $98.0 million to $103.0 million.
- Cash deployed for software development is expected to be in the range of $30 million - $35 million for the year ended December 31, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...